LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nasal Microbiome Influences Pneumonia and Related Diseases

By LabMedica International staff writers
Posted on 15 Jul 2019
Print article
Image: Digitally colorized photomicrograph of fluorescent antibody labeled Streptococcus pneumoniae bacteria in spinal fluid sample (Photo courtesy of the CDC).
Image: Digitally colorized photomicrograph of fluorescent antibody labeled Streptococcus pneumoniae bacteria in spinal fluid sample (Photo courtesy of the CDC).
A recent study examined the influence of the natural microbial flora in the nose and viral co-infection on the acquisition of Streptococcus pneumoniae bacteria and the development of pneumococcal diseases.

S. pneumoniae is the main bacterial pathogen involved in pneumonia. It has been speculated that acquisition of the bacteria and colonization density was probably affected by viral co-infections, the local microbiome composition, and mucosal immunity. To examine the relationship between the nasal microbiome and acquisition of S. pneumoniae bacteria, investigators at Liverpool School of Tropical Medicine (United Kingdom) and the University of Edinburgh (United Kingdom) used an experimental human challenge model (the Experimental Human Pneumococcal Challenge) and inoculated live bacteria in combination with a live virus in the form of the readily available nasal vaccine for influenza.

Working with this model, the investigators examined the interactions between live-attenuated influenza vaccine (LAIV), successive pneumococcal challenge, and the healthy adult nasal microbiota and mucosal immunity.

Results indicated that the equilibrium between the nasal microbiome and the host immune system had an impact on pneumococcal acquisition and density, in particular when combined with a viral co-infection. The microbial flora in the nose also appeared to have an effect on replication of the pathogenic virus itself.

Contributing author Dr. Daniela Ferreira, professor of respiratory vaccines and infection immunology at Liverpool School of Tropical Medicine, said, "We knew relatively little about the relationship between viral infections and the microbiota. Our model helped us to establish a link between baseline microbiota and colonization with the bacteria which causes pneumonia and shows the way that it is apparently altered with the introduction of a viral pathogen."

Senior author Dr. Debby Bogaert, professor of inflammation research at the University of Edinburgh, said, "Using this sophisticated human challenge model, we were for the first time able to identify that different constellations of microbes in the nose are associated with more or less inflammation, viral replication, and pneumococcal carriage receptiveness."

The work was published in the July 5, 2019, online edition of the journal Nature Communications.

Related Links:
Liverpool School of Tropical Medicine
University of Edinburgh

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.